Getinge (GETI.B) AI Stock Analysis

• Market Cap: kr61.12B
• Dividend Yield: 2.16%
• Average Volume (3M): 472.77K
• Price to Earnings (P/E): 29.8
• Beta (1Y): 0.84
• Revenue Growth: 6.74%
• EPS Growth: 21.40%
• Country: SE
• Employees: 11,827
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 2.42
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 671,507
• 30 Day Avg. Volume: 472,771
• PEG Ratio: -0.94
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 1.42
• P/FCF Ratio: 15.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr241.67
• Price Target Upside: 11.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: kr231.00 ▲(6.50% Upside)

Getinge's overall stock score is driven by its stable financial performance and moderate valuation. The technical analysis indicates a neutral trend, with no strong momentum signals. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates Getinge's ability to maintain and potentially expand its market position, reflecting strong demand for its products.

Cash Generation

Strong cash generation enhances Getinge's ability to invest in R&D, pay down debt, and return capital to shareholders, supporting long-term growth.

Balance Sheet Health

A moderate debt-to-equity ratio suggests a balanced approach to leveraging, providing financial stability and flexibility for future investments.

Negative Factors

Profit Margin Decline

A decline in net profit margin indicates rising costs or inefficiencies, which could pressure profitability if not addressed.

Return on Equity

Low return on equity suggests inefficiencies in generating returns for shareholders, potentially impacting investor confidence and capital allocation.

Operating Cash Flow Efficiency

Low operating cash flow efficiency may indicate challenges in converting income into cash, affecting liquidity and operational flexibility.

Getinge Business Overview & Revenue Model

Company Description

Getinge (GETI.B) is a global medical technology company that specializes in providing innovative solutions for healthcare and life sciences. The company operates primarily in three sectors: Surgical Workflows, Critical Care, and Life Science. Getinge's core products include surgical tables, operating room integration systems, advanced ventilators, cardiopulmonary products, and solutions for the biopharmaceutical industry, aimed at improving patient outcomes and enhancing operational efficiency in hospitals and laboratories.

How the Company Makes Money

Getinge generates revenue through the sale of medical devices, equipment, and services across its key sectors. The company has established multiple revenue streams, including the direct sale of its products to healthcare facilities, ongoing maintenance and service contracts, and consumables that accompany their devices. Additionally, Getinge benefits from partnerships with hospitals, research institutions, and other healthcare providers, which help to drive sales and foster long-term customer relationships. The company also invests in research and development to innovate and expand its product offerings, further contributing to its earnings through the introduction of new technologies that meet evolving market demands.

Getinge Financial Statement Overview

Summary

Getinge demonstrates a stable financial position with consistent revenue growth and strong cash flow generation. While profitability margins have seen slight declines, the company maintains a solid balance sheet with a healthy equity base.

Income Statement

Getinge's income statement shows a stable revenue growth trend with a TTM (Trailing-Twelve-Months) increase of 1.3%. Gross profit margin remains healthy at 46.9%, indicating efficient production processes. However, net profit margin has slightly decreased to 4.2%, suggesting increased costs or expenses. EBIT and EBITDA margins are solid, reflecting good operational efficiency, but have shown some decline compared to previous years.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.39, indicating a balanced approach to leveraging. Return on equity is at 4.9%, which is relatively low, suggesting room for improvement in generating returns for shareholders. The equity ratio stands at 51.4%, showing a strong equity base, which is a positive indicator of financial stability.

Cash Flow

Cash flow analysis reveals a robust free cash flow growth rate of 16%, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.31, which is lower than ideal, suggesting potential inefficiencies in converting income into cash. However, the free cash flow to net income ratio of 0.67 is healthy, reflecting good cash management practices.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	88.16B	34.76B	31.83B	28.29B	27.05B	29.82B
Gross Profit	40.31B	16.15B	14.49B	13.41B	13.58B	14.72B
EBITDA	16.89B	5.31B	5.93B	5.73B	6.15B	6.46B
Net Income	5.24B	1.64B	2.41B	2.49B	2.97B	3.24B
Balance Sheet
Total Assets	56.79B	63.92B	53.59B	52.03B	44.55B	45.01B
Cash, Cash Equivalents and Short-Term Investments	2.85B	2.96B	2.73B	5.68B	4.08B	6.06B
Total Debt	11.43B	10.73B	8.08B	5.82B	4.31B	10.21B
Total Liabilities	27.41B	30.71B	23.18B	21.58B	19.38B	23.53B
Stockholders Equity	29.18B	33.01B	30.17B	30.04B	24.75B	21.02B
Cash Flow
Free Cash Flow	7.85B	3.27B	1.60B	2.23B	5.63B	6.15B
Operating Cash Flow	11.03B	4.58B	2.96B	3.37B	6.56B	7.20B
Investing Cash Flow	-6.64B	-4.55B	-6.54B	-1.47B	-1.33B	-1.99B
Financing Cash Flow	-934.00M	504.00M	511.00M	-500.00M	-7.24B	-297.00M

Getinge Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 216.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 216.9 is above the 20-day moving average (MA) of 214.56, above the 50-day MA of 215.61, and above the 200-day MA of 202.38, indicating a bullish trend. The MACD of 2.92 indicates Negative momentum. The RSI at 65.18 is Neutral, neither overbought nor oversold. The STOCH value of 88.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.

Getinge Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr17.68B	40.07	3.34%	0.80%	-1.29%	―
CEVI	68 Neutral	kr3.84B	25.36	17.89%	1.61%	1.53%	0.79%
GETI.B	66 Neutral	kr61.12B	29.76	6.91%	2.16%	6.74%	21.40%
XVIVO	63 Neutral	kr6.14B	203.01	1.32%	―	8.39%	-85.36%
SECT.B	58 Neutral	kr46.59B	71.18	38.97%	0.43%	10.08%	68.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	kr983.44M	-23.95	-4.42%	―	13.48%	28.98%

Getinge Corporate Events

Getinge to Strengthen Board with Former Novo Nordisk Executive Camilla Sylvest

Getinge’s Nomination Committee plans to propose seasoned healthcare executive Camilla Sylvest for election to the company’s Board of Directors at the 2026 Annual General Meeting, while long-serving board member Malin Persson has declined re-election after more than a decade of service. Sylvest’s extensive commercial and leadership experience from Novo Nordisk, including oversight of global strategy and major product launches in diabetes, obesity and cardiovascular disease, as well as her current board role at biotechnology group argenx, would strengthen Getinge’s governance with deep expertise in high-growth therapeutic areas and global market development, potentially sharpening the company’s strategic positioning in the competitive medtech and life sciences landscape.

The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK231.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.